Not admitted · Not a forecast
Rules 1.1.0 · as of 14 Sep 2026
Owen Scott Muir · Said 4 Mar 2023 · owen-0331
Quote
Not a forecast
“Just as the FDA moves to re-classify the intranasal version as an OTC drug, another threat to the lives of those struggling with addiction is here to frustrate our efforts.”
Opening of the xylazine (Tranq) post. The author notes the FDA is moving to reclassify intranasal naloxone (Narcan) as an over-the-counter drug; later he repeats that Narcan is 'recommended for reclassification as an over-the-counter medicine by the FDA'. The regulatory decision is pending at the post date (2023-03-04).
Descriptive, retrospective, or a statement of preference; no future state asserted.